Megan Kruse, MD

Learn how to spot T-DXd lung toxicity early, manage fatigue and nausea, and tailor HER2+ breast cancer care with emerging biomarker insights.

Experts weigh TDxd’s real-world tolerability, trial gaps, and biomarkers guiding escalation or de-escalation in HER2+ breast cancer care.

Clinicians share practical tips to spot T-DXd lung toxicity early, manage nausea and fatigue, and counsel on hair loss options.

Clinicians weigh earlier T‑DXd use in breast cancer by preventing nausea, managing fatigue via dose reductions, and closely monitoring ILD risk in curative settings.

Experts discuss evolving care for HER2-positive metastatic breast cancer brain metastases, highlighting CNS-active drugs, earlier MRI screening, and smarter treatment decisions.

Experts weigh first-line HER2+ metastatic breast cancer options, when to start T-DXd plus pertuzumab, and how patient risks shape durable response.

Clinicians weigh T-DXd plus pertuzumab vs CLEOPATRA, balancing lung risk, fitness and de novo disease to personalize HER2+ care.

ASCO insights on T-DXd plus pertuzumab in HER2-positive breast cancer: deep, durable responses and practical ILD/radiation safety considerations.

New phase III data reshapes HER2+ breast cancer care, spotlighting T-DXd from neoadjuvant to first-line metastatic, plus CNS and toxicity insights.

The hematology and medical oncology expert described the implementation of biosimilars into treating patients with breast cancer.